CTLA-4 Blockade-Based Immunotherapy in Prostate Cancer
Abstract
This research project investigated immunotherapy for prostate cancer. Specifically, we explored the use of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in combination with blockade of a T cell inhibitory molecule called Cytotoxic T-Lymphocyte-Associated Molecule-4 (CTLA-4). We studied repetitive dosing of an anti-CTLA-4 antibody in combination with subcutaneous GM-CSF to determine the safety of this combination. Concomitantly, peripheral blood was being collected from patients to evaluate the immune response generated. The original plan was to move this combination therapy into a phase II trial to look at effects on PSA and other clinical endpoints in patients failing prior vaccination for prostate cancer. This is not possible for a number of reasons. The significant autoimmune toxicity observed (which appears required for an anti-tumor effect) may preclude administration of this combination in prostate cancer patients who are often elderly with comorbidities. Further, the availability of this CTLA-4 antibody is limited. Thus, the current project will end with completion of the phase I trial noted here.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2007
- Accession Number
- ADA470131
Entities
People
- Brian I. Rini